← Back to overview

MRK Merck & Company, Inc.

Pharmaceuticals · $131.07 +0.45%
EN PL
Price Alert:

Compare

Shows % change over the period so different-priced stocks can be compared fairly.

Technical Indicators

RSI (14)
50.9
Relative Strength Index (RSI): measures how fast and how much the price has moved recently, on a 0-100 scale. Above 70 is often called "overbought" (may be due for a pause or pullback); below 30 is "oversold" (may be due for a bounce). It is not a guarantee either way.
SMA 20 / 50 / 200
131.27 / 130.80 / —
Moving Averages (SMA): the average closing price over the last N days, smoothing out day-to-day noise. When price trades above its moving averages, and shorter averages are above longer ones, it is generally read as a healthier trend.
MACD / Signal
0.17 / 0.24
MACD: compares two moving averages (12-day and 26-day) to gauge momentum. When the MACD line crosses above its signal line, momentum is turning up; crossing below suggests momentum turning down.

Fundamentals

P/E
36.9
Price-to-Earnings ratio: how many dollars investors pay for $1 of the company's annual profit. Higher usually means the market expects faster growth (or the stock is expensive); lower can mean it's cheap — or that growth is expected to slow.
Market Cap
323.72B
Market Capitalization: the total value of all the company's shares — share price × number of shares. A rough measure of company size.
Div Yield
2.61%
Dividend Yield: the annual cash dividend paid to shareholders, as a percentage of the current share price.
52-Week Range
76.66 – 131.74
52-Week Range: the lowest and highest price the stock has traded at over the last year. Where the price sits in this range hints at recent strength or weakness.

Trend Analysis

Merck & Company, Inc. is trading at $131.07, +0.45% versus the previous close. The price is near its 52-week high — the top of its recent trading range.
RSI is in a neutral range — no strong overbought/oversold signal.
MACD is below its signal line — momentum currently leans negative.
Combine this reading with the fundamentals below before forming a view — no single indicator is a guarantee of what happens next.

Latest News

The 3.4% Income Play That Beats the Dogs of the Dow Strategy
24/7 Wall St. · 2026-07-25 16:24
Johnson & Johnson Is Becoming A Narrower Company Than You Bought
Trefis · 2026-07-25 14:30
This Catalyst Makes Eli Lilly a Top Growth Stock in 2026
24/7 Wall St. · 2026-07-24 17:30
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus
Zacks · 2026-07-24 13:10
Par Health Launches First and Only Generic Version of Janumet® XR (sitagliptin and metformin HCl extended-release) Tablets in the United States
PR Newswire · 2026-07-24 12:00
Merck Outlines Access Plan for Investigational Monthly HIV Prevention Pill
MT Newswires · 2026-07-24 11:22
Gilead Sciences Says EMA Recommends Trodelvy-Keytruda Combination for Breast Cancer
MT Newswires · 2026-07-24 10:55
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
Business Wire · 2026-07-24 10:45
Educational information only. Nothing here is investment advice — always do your own research and consider talking to a licensed financial advisor before buying or selling.
Data: Yahoo Finance, refreshed periodically and cached locally.